APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy (HE) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast 2026-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy (HE) Therapeutics Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy (HE) Therapeutics Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy (HE) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy (HE) Therapeutics Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy (HE) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hepatic Encephalopathy (HE) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hepatic Encephalopathy (HE) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hepatic Encephalopathy (HE) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hepatic Encephalopathy (HE) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hepatic Encephalopathy (HE) Therapeutics include ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt and Valeant, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hepatic Encephalopathy (HE) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hepatic Encephalopathy (HE) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Hepatic Encephalopathy (HE) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hepatic Encephalopathy (HE) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hepatic Encephalopathy (HE) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hepatic Encephalopathy (HE) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Hepatic Encephalopathy (HE) Therapeutics Segment by Company

ASKA Pharmaceutical

COSMO PHARMACEUTICALS

Mallinckrodt

Valeant

Hepatic Encephalopathy (HE) Therapeutics Segment by Type

Probiotics

Neomycin

Lactulose

Thiamine

Rifaximin

Hepatic Encephalopathy (HE) Therapeutics Segment by Application

Acute Liver Failure

Liver Cirrhosis

Hepatic Encephalopathy (HE) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy (HE) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy (HE) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy (HE) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hepatic Encephalopathy (HE) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hepatic Encephalopathy (HE) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatic Encephalopathy (HE) Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Probiotics Major Player Table 3. Neomycin Major Player Table 4. Lactulose Major Player Table 5. Thiamine Major Player Table 6. Rifaximin Major Player Table 7. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Acute Liver Failure Major Player Table 9. Liver Cirrhosis Major Player Table 10. Hepatic Encephalopathy (HE) Therapeutics Industry Trends Table 11. Hepatic Encephalopathy (HE) Therapeutics Industry Drivers Table 12. Hepatic Encephalopathy (HE) Therapeutics Industry Opportunities and Challenges Table 13. Hepatic Encephalopathy (HE) Therapeutics Industry Restraints Table 14. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2021-2026) Table 17. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2027-2032) Table 19. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Players (2021-2026) Table 21. Global Hepatic Encephalopathy (HE) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Hepatic Encephalopathy (HE) Therapeutics Key Players Headquarters & Area Served Table 23. Global Hepatic Encephalopathy (HE) Therapeutics Players, Product Type & Application Table 24. Global Hepatic Encephalopathy (HE) Therapeutics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Hepatic Encephalopathy (HE) Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2021-2026) Table 36. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2027-2032) Table 37. ASKA Pharmaceutical Company Information Table 38. ASKA Pharmaceutical Business Overview Table 39. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 41. ASKA Pharmaceutical Recent Development Table 42. COSMO PHARMACEUTICALS Company Information Table 43. COSMO PHARMACEUTICALS Business Overview Table 44. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 46. COSMO PHARMACEUTICALS Recent Development Table 47. Mallinckrodt Company Information Table 48. Mallinckrodt Business Overview Table 49. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 51. Mallinckrodt Recent Development Table 52. Valeant Company Information Table 53. Valeant Business Overview Table 54. Valeant Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Valeant Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 56. Valeant Recent Development Table 57. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 58. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 59. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 60. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 61. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 62. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 63. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 64. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 65. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 66. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 67. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 68. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 69. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 70. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 71. China Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 72. China Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 73. China Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 74. China Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 75. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 76. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 77. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 78. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 79. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 80. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 81. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 82. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 83. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 84. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 85. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 86. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 88. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy (HE) Therapeutics Image Figure 2. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Probiotics Image Figure 5. Neomycin Image Figure 6. Lactulose Image Figure 7. Thiamine Image Figure 8. Rifaximin Image Figure 9. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 11. Acute Liver Failure Image Figure 12. Liver Cirrhosis Image Figure 13. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million) & (2021-2032) Figure 14. Global Hepatic Encephalopathy (HE) Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Hepatic Encephalopathy (HE) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032) Figure 26. North America Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032) Figure 27. North America Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Country (2021-2032) Figure 28. United States Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032) Figure 33. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032) Figure 34. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Country (2021-2032) Figure 35. Germany Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032) Figure 45. China Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032) Figure 48. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032) Figure 49. Asia Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Region (2021-2032) Figure 50. Japan Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032) Figure 58. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032) Figure 59. SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Country (2021-2032) Figure 60. Brazil Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Hepatic Encephalopathy (HE) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Probiotics
  • Neomycin
  • Lactulose
  • Thiamine
  • Rifaximin
Applications
  • Acute Liver Failure
  • Liver Cirrhosis
Companies covered
  • ASKA Pharmaceutical
  • COSMO PHARMACEUTICALS
  • Mallinckrodt
  • Valeant

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hepatic Encephalopathy (HE) Therapeutics Market by Type
  3. 1.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Probiotics
  5. 1.2.3 Neomycin
  6. 1.2.4 Lactulose
  7. 1.2.5 Thiamine
  8. 1.2.6 Rifaximin
  9. 1.3 Hepatic Encephalopathy (HE) Therapeutics Market by Application
  10. 1.3.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Acute Liver Failure
  12. 1.3.3 Liver Cirrhosis
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Hepatic Encephalopathy (HE) Therapeutics Market Dynamics
  1. 2.1 Hepatic Encephalopathy (HE) Therapeutics Industry Trends
  2. 2.2 Hepatic Encephalopathy (HE) Therapeutics Industry Drivers
  3. 2.3 Hepatic Encephalopathy (HE) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy (HE) Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Hepatic Encephalopathy (HE) Therapeutics Growth Trends by Region
  3. 3.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Players
  2. 4.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hepatic Encephalopathy (HE) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hepatic Encephalopathy (HE) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hepatic Encephalopathy (HE) Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Hepatic Encephalopathy (HE) Therapeutics Players, Product Type & Application
  8. 4.5 Global Hepatic Encephalopathy (HE) Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hepatic Encephalopathy (HE) Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Hepatic Encephalopathy (HE) Therapeutics Tier 1, Tier 2, and Tier 3
5 Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
  1. 5.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2021-2032)
6 Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
  1. 6.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 ASKA Pharmaceutical
  2. 7.1.1 ASKA Pharmaceutical Company Information
  3. 7.1.2 ASKA Pharmaceutical Business Overview
  4. 7.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  6. 7.1.5 ASKA Pharmaceutical Recent Developments
  7. 7.2 COSMO PHARMACEUTICALS
  8. 7.2.1 COSMO PHARMACEUTICALS Company Information
  9. 7.2.2 COSMO PHARMACEUTICALS Business Overview
  10. 7.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  12. 7.2.5 COSMO PHARMACEUTICALS Recent Developments
  13. 7.3 Mallinckrodt
  14. 7.3.1 Mallinckrodt Company Information
  15. 7.3.2 Mallinckrodt Business Overview
  16. 7.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  18. 7.3.5 Mallinckrodt Recent Developments
  19. 7.4 Valeant
  20. 7.4.1 Valeant Company Information
  21. 7.4.2 Valeant Business Overview
  22. 7.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Valeant Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  24. 7.4.5 Valeant Recent Developments
8 North America
  1. 8.1 North America Hepatic Encephalopathy (HE) Therapeutics Revenue (2021-2032)
  2. 8.2 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Country
  11. 8.6.1 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Country
  11. 9.6.1 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hepatic Encephalopathy (HE) Therapeutics Revenue (2021-2032)
  2. 10.2 China Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Country
  11. 11.6.1 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hepatic Encephalopathy (HE) Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst